Logo for bluebird bio Inc

bluebird bio Investor Relations Material

Latest events

Logo for bluebird bio Inc

Q3 2024

bluebird bio
Logo for bluebird bio

Q3 2024

14 Nov, 2024
Logo for bluebird bio

Status Update

24 Sep, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from bluebird bio Inc

Access all reports
Segment Data
Access more data
Revenue by
Source
Product revenue
Other
Expenses by
Financials
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company's product portfolio comprises two clinical-stage lentiviral-based gene therapy product candidates for the treatment of transfusion-dependent b-thalassemia (TDT) and severe sickle cell disease (SCD); and a preclinical-stage gene therapy product candidate for the treatment of childhood cerebral adrenoleukodystrophy. Its clinical development programs include LentiGlobin BB305 program to treat TDT and SCD; and Lenti-D that is in Phase II/III trial to treat cerebral adrenoleukodystrophy. The company has collaboration agreements with Celgene Corporation; Intellia Therapeutics, Inc.; Catalent Biologics LLC; Kite Pharma, Inc.; Genethon S.A.; and University of Pennsylvania. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts